Skip to main content
Log in

Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs

  • Original Articles
  • Cytosine Arabinoside, Pharmacokinetics, Dogs
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Cytosine arabinoside (ara-C) is a component of many protocols for the treatment of CNS (central nervous system) leukemia and lymphoma in humans and dogs. It is also used for the prophylaxis of CNS metastasis in acute lymphoblastic leukemia. Although ara-C enters the cerebrospinal fluid (CSF) of human cancer patients after i.v. administration, it is unclear whether a similar CNS distribution occurs in humans whose blood-brain barrier has not been compromised by invasive disease. No information on the penetration of ara-C into the CSF in dogs is available. We studied the plasma and CSF pharmacokinetics of 600 mg/m2 ara-C in ten healthy male dogs after its administration as a rapid i.v. bolus (six dogs) or as a 12-h i.v. infusion (four dogs). Ara-C concentration in blood and CSF samples was determined by high-performance liquid chromatography (HPLC). After an i.v. bolus of ara-C, the mean plasma distribution half-life was 7.1±4.5 min and the mean elimination half-life was 69±28 min. The mean plasma clearance was 227±125 ml min−1 m−2. The peak concentration of ara-C in the CSF was 29±11 μm, which occurred at 57±13 min after the ara-C bolus. The CSF elimination half-life was 113±26 min. During a 12-h infusion of ara-C (50 mg m−2 h−1), the plasma steady-state concentration was 14.1±4.2 μm, the CSF steady-state concentration was 8.3±1.1 μm, and the CSF: plasma ratio was 0.62±0.14. The plasma eleimination half-life was 64±19 min and the plasma clearance was 214±69 ml min−1 m−2. The CSF elimination half-life was 165±28 min. No clinically significant toxicity was observed over a 21-day period following drug administration in either of the treatment groups. Our data indicate that ara-C crosses the blood-brain barrier in normal dogs and that i.v. administration of this drug has potential as a treatment modality for neoplasia involving the CNS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R (1989) Pharmacology studies of 1β-d-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res 49: 241–247

    Google Scholar 

  2. Band PR, Holland JF, Bernard J, Weil M, Walker M, Rall D (1973) Treatment of central nervous system leukemia with intrathecal cytosine arabinoside. Cancer 32: 744–748

    Google Scholar 

  3. Breithaupt H, Pralle H, Eckhardt T, Von Hattingberg M, Schick J, Loffler H (1982) Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). Cancer 50: 1248–1257

    Google Scholar 

  4. Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng Y-C (1983) Alteration of the pharmacokinetics of high-dose ara-C by its metabolite ara-U in patients with acute leukemia. J Clin Oncol 1: 763–771

    Google Scholar 

  5. Champlin R, Ho W, Winston D, Decker R, Greenberg P, Burnison M, Holly FE, Gale RP (1987) Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. Semin Oncol 14: 1–6

    Google Scholar 

  6. Couto CG, Cullen J, Pedroia V, Turrel JM (1984) Central nervous system lymphosarcoma in the dog. J Am Vet Med Assoc 184: 809–813

    Google Scholar 

  7. Crow SE (1982) Lymphosarcoma (malignant lymphoma) in the dog: diagnosis and treatment. Compend Cont Educ Pract 4: 283–289

    Google Scholar 

  8. Damon LE, Linker CA (1989) Comparison of plasma and cerebrospinal fluid pharmacokinetics of high-dose versus intermediatedose cytosine arabinoside (abstract). Proceedings, Annual Meeting of the American Society of Clinical Oncologists, 8, p 267

    Google Scholar 

  9. DeLoach JR, Barton C (1982) Circulating carrier erythrocytes: slow-release vehicle for an antileukemic drug, cytosine arabinoside. Am J Vet Res 43: 2210–2212

    Google Scholar 

  10. Early AP, Preisler HD, Slocum H, Rustum YM (1982) A pilot study of high-dose 1-β-d-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 42: 1587–1594

    Google Scholar 

  11. Ellens H, Rustum Y, Mayhew E, Ledesma E (1982) Distribution and metabolism of liposome-encapsulated and free 1-β-d-arabinofuranosylcytosine (ara-C) in dog and mouse tissues. J Pharmacol Exp Ther 222: 324–330

    Google Scholar 

  12. Frick J, Ritch PS, Hansen RM, Anderson T (1984) Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 2: 365–368

    Google Scholar 

  13. Fulton DS, Levin VA, Gutin PH, Edwards MSB, Seager ML, Stewart J, Wilson CB (1982) Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 8: 285–291

    Google Scholar 

  14. Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl J Med 300: 1189–1199

    Google Scholar 

  15. Hande KR, Stein RS, McDonough DA, Greco FA, Wolff SN (1982) Effects of high-dose cytarabine. Clin Pharmacol Ther 31: 669–674

    Google Scholar 

  16. Harris AL, Potter C, Bunch C, Boutagy J, Harvey DJ, Grahame-Smith DG (1979) Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 8: 219–227

    Google Scholar 

  17. Herman TS, Hammond N, Jones SE, Butler JJ, Byrne GE, McKelvey EM (1979) Involvement of the central nervous system by non-Hodgkin's lymphoma. Cancer 43: 390–397

    Google Scholar 

  18. Ho DHW, Frei E III (1971) Clinical pharmacology of 1-β-d-arabinofuranosylcytosine. Clin Pharmacol Ther 12: 944–954

    Google Scholar 

  19. Ho DHW, Carter CJK, Loo TL, Abbott RL, McBride CM (1975) Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs. Drug Metab Dispos 3: 309–313

    Google Scholar 

  20. Hoff HE, Deavers S, Huggins RA (1966) Effects of hypertonic glucose and mannitol on plasma volume. Proc Soc Exp Biol Med 122: 630–634

    Google Scholar 

  21. Law IP, Blom J (1977) Adult acute leukemia. Frequency of central nervous system involvement in long term survivors. Cancer 40: 1304–1306

    Google Scholar 

  22. Perlow L, Ohnuma T, Andrejczuk A, Shafir M, Strauchen J, Holland JF (1985) Pharmacology and toxicology of a seven-day infusion of 1-β-d-arabinofuranosylcytosine plus uridine in dogs. Cancer Res 45: 2572–2577

    Google Scholar 

  23. Regazzi MB, Rondanelli R, Morra E, Lazzarino M, Alessandrino EP, Bernasconi C (1989) Ara-C pharmacokinetics in meningeal leukemia treatment (abstract). J Chemother Infect Dis Malig 1 [Suppl 1]: 279

    Google Scholar 

  24. Rohrig KE (1983) Acute myelomonocytic leukemia in a dog. J Am Vet Med Assoc 182: 137–141

    Google Scholar 

  25. Rustum YM, Riva C, Preisler HD (1987) Pharmacokinetic parameters of 1-β-d-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute non-lymphocytic leukemia treated with conventional and high-dose ara-C. Semin Oncol 14 [Suppl 1]: 141–148

    Google Scholar 

  26. Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA (1982) The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol 10 [Suppl 1]: 157–168

    Google Scholar 

  27. Spriggs DR, Robbins G, Arthur K, Mayer RJ, Kufe D (1988) Prolonged high-dose ara-C infusions in acute leukemia. Leukemia 2: 304–306

    Google Scholar 

  28. Stewart DJ, Keating MJ, McCredie KB, Smith TL, Youness E, Murphy SG, Bodey GP, Freirich EJ (1981) Natural history of central nervous system acute leukemia in adults. Cancer 47: 184–196

    Google Scholar 

  29. Stewart DJ, Hugenholtz H, DaSilva V, Benoit B, Richard M, Russell N, Maroun J, Verma S (1987) Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas. Semin Oncol 14: 110–115

    Google Scholar 

  30. Sullivan MP (1982) Use of cytosar in pediatric acute myelocytic leukemia and leukemic meningitis. Med Pediatr Oncol 10 [Suppl 1]: 193–200

    Google Scholar 

  31. Sweet DL, Golomb HM, Ultman JE, Miller JB, Stein RS, Lester EP, Mintz U, Bitran JD, Streuli RA, Daly K, Roth NO (1980) Cyclophosphamide, vincristine, methotrexate with leucoverin rescue and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 92: 785–790

    Google Scholar 

  32. Theilen GH, Worley M, Benjamini E (1977) Chemoimmunotherapy for canine lymphosarcoma. J Am Vet Med Assoc 170: 607–610

    Google Scholar 

  33. Van Prooijen R, Van der Kleijn E, Haanen C (1977) Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. Clin Pharmacol Ther 21: 744–750

    Google Scholar 

  34. Wang JJ, Pratt CB (1970) Intrathecal arabinosyl cytosine in meningeal leukemia. Cancer 25: 531–534

    Google Scholar 

  35. Weller RE, Theilen GH, Madewell BR (1982) Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia. J Am Vet Med Assoc 181: 891–893

    Google Scholar 

  36. Ziegler JL, Bluming AZ (1971) Intrathecal chemotherapy in Burkitt's lymphoma. BMJ 3: 508–512

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by the Canine Disease Research Fund and in part by the Elsa U. Pardee Foundation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott-Moncrieff, J.C.R., Chan, T.C.K., Samuels, M.L. et al. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. Cancer Chemother. Pharmacol. 29, 13–18 (1991). https://doi.org/10.1007/BF00686329

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686329

Keywords

Navigation